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NESThe E3 Ubiquitin ligase TRIM50 promotes the formation and clearance of aggresome-associated polyubiquitinated
proteins through HDAC6 interaction, a tubulin speciﬁc deacetylase that regulates microtubule-dependent
aggresome formation. In this report we showed that TRIM50 is a target of HDAC6 with Lys-372 as a critical residue
for acetylation. We identiﬁed p300 and PCAF as two TRIM50 acetyltransferases and we further showed that a
balance between ubiquitination and acetylation regulates TRIM50 degradation.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The TRIM family comprises proteins that act as E3 ubiquitin ligases
in regulating a plethora of biological processes [1]. TRIM50 has been re-
cently associated with the dynamic movement of intracellular vesicles
and of gastric parietal cells in mice knock out model [2]. We previously
reported that TRIM50 encodes an E3 ubiquitin ligase [3] that interacts
with the adapter protein p62/SQSTM1 andwith theHistoneDeacetylase
6 (HDAC6) [4]. Furthermore we showed that TRIM50 promotes the
recruitment of polyubiquitinated proteins into the aggresome, contrib-
uting to their clearance [4].
Protein lysine acetylation has emerged as a key posttranslational
modiﬁcation (PTM) in gene expression regulation, protein stability and
signal transduction [5], through the modiﬁcation of histones and nuclear
and cytoplasmic components, ranging from transcription factors to
receptor proteins.
Protein acetylation is a dynamic process controlled by the antagonistic
actions of two large families of enzymes: the histone acetyltransferases
(HATs) and the histone deacetylases (HDACs). The balance between the
activities of these enzymes serves as a key regulatory mechanism for
gene expression and governs numerous developmental processes and
disease states. HATs commonly catalyze the transfer of an acetyl group
fromacetyl-CoA to the terminal amine on the side chain of lysine residuesS Casa Sollievo della Sofferenza,
Rotondo (FG), Italy. Tel.: +39
ghts reserved.of proteins. At least two independent HATs, namely p300 and PCAF, reg-
ulate the activity of non-histone proteins pointing out HATs asmultifunc-
tional factors [6]. In humans, there are 18 potential histone deacetylases
enzymes, HDAC1 to HDAC11 and SIRT1 to SIRT7, which are responsible
for the removal of acetyl groups and maintenance of the equilibrium of
lysine acetylation in histones. Like HATs, histone deacetylases also pos-
sess substrate speciﬁcity and accumulating evidences suggest that
many, if not all, HDACs can deacetylate also non-histone proteins [5].
Additionally, since lysines also provide speciﬁc sites for other PTMs,
their acetylation would chemically lock the residue, conferring to this
modiﬁcation a regulatory potentialwith the ability to interferewith cel-
lular functions relying on other lysine modiﬁcations, i.e., methylation,
sumoylation, neddylation, biotinylation, and ubiquitination [7].
Ubiquitination is one of the most abundant and versatile PTMs in
cells where the ubiquitin is covalently added to lysine residues. In
humans, the ubiquitination is catalyzed by N500 E3 ligases. There are
several types of ubiquitin modiﬁcations with different effects on target
proteins, for instance the polyubiquitination is the triggering signal
that promotes their proteasomal degradation. A cross-regulation
between lysine acetylation and ubiquitination was found as a critical
regulatory mechanism. Besides a direct competition for the lysine
being modiﬁed, a more complex process connect the two signalling
pathways, for instance the acetylation improves proteins stability by
inhibiting ubiquitin-dependent degradation [7].
In the present study, we report that TRIM50 is acetylated by PCAF and
p300. We found that HDAC6 deacetylases TRIM50 in a microtubule-
dependent manner and that acetylation and ubiquitination compete for
the same lysine residue.
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2.1. Fusion plasmids and mutagenesis
The FLAG-TRIM50 stable cell line, pcDNA3-EGFP wild-type and
mutants TRIM50were described in [4]. TRIM50Dom.1-2-3 were cloned
into a pcDNA3-EGFP vector using a PCR basedmethodwith appropriate
oligonucleotides followed by in-frame insertion into the vector. EGFP-
TRIM50_K372R, EGFP-TRIM50_Del372-374, EGFP-TRIM50ΔNES1-2-3
and EGFP-TRIM50 Dom.1ΔNES3 were generated by site-directed muta-
genesis via QuickChange II kit (Stratagene) using EGFP-TRIM50 and
EGFP-TRIM50 Dom.1 as templates, respectively. HDAC6 mutants were
a gift of Prof. P.Matthias (FriedrichMiescher Institute for Biomedical Re-
search, Basel, Switzerland). FLAG-PCAF and HA-p300were a gift of Prof.
E. Seto (Molecular Oncology Program, H. Lee Mofﬁtt Cancer Center and
Research Institute, Tampa, USA).
2.2. Cell lines
HEK293, HeLa (all from ATCC, Manassas, USA) and MEF Hdac6 cell
linesweremaintained in DMEMwith Glutamaxmedium supplemented
with 10% fetal bovine serum and 1% antibiotics (Invitrogen, Carlsbad,
CA). Fugene HD (Promega) was used for transfection according to the
manufacturers' instructions.
2.3. Immunoﬂuorescence microscopy
For immunoﬂuorescence analyses, the cells transfected with EGFP-
TRIM50 and EGFP-TRIM50 mutants were ﬁxed before their incubation
with the primary and secondary antibodies of interest, mounted in
mowiol and examined on a Zeiss LSM 510 META confocal microscope
(Carl Zeiss, Jena, Germany). All confocal images were obtained using
the necessary ﬁlter sets for GFP, Alexaﬂuor 488 and 546, using a Zeiss
Plan-Neoﬂuor 63× oil immersion objective (NA 1.4), with the pinhole
set to one Airey unit. HDAC6 antibody (Santa Cruz) was used at 1:200
dilution, where is indicated.
2.4. Immunoprecipitation and western blot
Co-immunoprecipitation experiments were performed using
Dynabeads magnetic beads (Invitrogen) following manufacturer's
instructions. Complexes were analyzed by western blotting using
indicated antibodies: anti-EGFP, anti-ubiquitin (Santa Cruz), anti-Ack
(Cell Signaling), anti-FLAG (Sigma) and anti-HA (Covance). Horseradish
peroxidase conjugated anti-mouse (GE Healthcare) and anti-rabbit
(Santa Cruz) antibodies and the ECL chemiluminescence system
(GE Healthcare) were used for detection. Where indicated the MG132
proteasome inhibitor (Calbiochem, USA)was added to the cell medium.
2.5. Statistical analysis
All microscopy experiments were performed at least in triplicate.
Approximately 100 cells were analyzed for each experimental condi-
tion. Variations of localizations were evaluated on the basis of Student's
t-test.
3. Results
3.1. TRIM50 is acetylated at K372 site
As elsewhere demonstrated, TRIM50 interactswithHDAC6, an inter-
action strengthens in the presence of the proteasome inhibitor MG132
[4]. To map the domain(s) of HDAC6 that binds TRIM50 we performed
co-immunoprecipitation assays with different HDAC6 truncating
mutants in the presence of MG132. As reported in Fig. 1(B–D) only
the two constructs containing the ﬁrst deacetylase (CAT1) domain,HDAC6_DBUZ and HDAC6 (1-503), interact with TRIM50 indicating
that CAT1 is necessary for TRIM50 interaction.
The association between TRIM50 and the catalytic HDAC6 domain
suggests that TRIM50may be a deacetylation target of HDAC6. To assess
this, two TRIM50 constructs, tagged with FLAG and EGFP respectively,
were immunoprecipitated and an anti-acetyl-lysine speciﬁc antibody
was used for immunodetection of acetylated-TRIM50. Acetylated
form(s) of TRIM50were detected showing that TRIM50 is an acetylated
protein (Figs. 1E and 2B). Moreover a TRIM50mutant construct lacking
the C-Terminal region (EGFP-TRIM50_Dom1) (schematized in Fig. 2A)
was unable of being acetylated, hinting that RFP domain is involved in
acetylation (Fig. 2B). Next we searched for putative lysine residues of
TRIM50 involved in acetylation. Computational prediction revealed
the presence of two evolutionarily conserved lysines, K372 and K374,
as the more likely acetylation sites in the C-terminal TRIM50 region
(Fig. 2C). Therefore, to assess the acetylated residues in TRIM50 protein,
by directmutagenesis we generated the two EGFP-TRIM50_Del372-374
and EGFP-TRIM50_K372R constructs and performed immunoprecipita-
tion assays using an EGFP antibody. These studies revealed that both
TRIM50_Del372-374 and TRIM50_K372R mutant proteins did not
undergo to acetylation modiﬁcations when compared to TRIM50 wild-
type construct, hinting that K372 residue is a target of acetylation
(Fig. 2D).
3.2. p300 and PCAF are acetyltransferases of TRIM50
Acetylation Set Enrichment-Based software (ASEB; http://202.38.
126.151/hmdd/huac/) predicted CBP/p300 and PCAF as acetylase pro-
teins associated to K372 residue of TRIM50. By immunoblotting assays
we showed that ectopic expression of p300 and PCAF increased the
level of acetylated TRIM50, although with different strength (Fig. 2E).
3.3. HDAC6 deacetylates TRIM50 in a microtubule-dependent manner
Since the catalytic CAT1 domain of HDAC6 is involved in TRIM50 in-
teraction and TRIM50 is acetylated, we asked whether HDAC6 is a
deacetylase of TRIM50. As shown in Fig. 2F, the overexpression of HA-
HDAC6 abrogates TRIM50 acetylation. To conﬁrm this result, we
transfected Mouse Embryo Fibroblasts (MEFs) derived from Hdac6 +/+
and −/y mice with EGFP-TRIM50 and we found that TRIM50 acetylation
increased in Hdac6 −/y cell lines, providing additional evidence for a
role of HDAC6 in mediating TRIM50 deacetylation (Fig. 2G). Finally, we
used Trichostatin A (TSA), a deacetylase inhibitor of class I/II HDAC family
enzymes (Fig. 2E and H). By immunoprecipitation assay we found that
TSA increased TRIM50 acetylation level. Collectively, these data indicate
that HDAC6, through its ﬁrst catalytic domain, interacts with and regu-
lates TRIM50 acetylation in K372 residue.
Since HDAC6 and TRIM50 possess both a microtubule-binding
capacity we assessed whether microtubules integrity is required for
TRIM50 deacetylation. We treated the FLAG-TRIM50#3, a HEK293 cell
line stably expressing a FLAG-TRIM50 construct, in ice for 1 h, a treat-
ment that leads to complete depolymerization of microtubule network
[8]. After microtubule depolymerization, by immunoprecipitating
TRIM50 protein and blotting with the acetyl-lysine antibody we
observed an increase of TRIM50 acetylation level. This increase was
persisting even in the presence of HDAC6 (Fig. 3A). Overall, these results
indicate that an intact microtubule network is required for HDAC6 to
deacetylase TRIM50.
3.4. TRIM50 acetylation antagonizes TRIM50 ubiquitination
TRIM50 is regulated by ubiquitination [3]. Since acetylation can com-
pete with the ubiquitination in targeting proteins [9] we asked whether
acetylation competes with and may inhibit TRIM50 ubiquitination. To
assess this, we analyzed the ubiquitination level of TRIM50 and of
K372-TRIM50 mutant protein. A higher ubiquitination level of TRIM50
Fig. 1. TRIM50 is acetylated in vivo. (A) Schematic representation of HDAC6 deletion mutants with the minimal region of interaction between TRIM50 and HDAC6 depicted in
gray. (B–C) HEK293 transiently transfected with EGFP-TRIM50 and FLAG-HDAC6 deletion mutants were treated with 25 μM of MG132 for 6 h, immunoprecipitated with anti-FLAG
and immunoblotted with anti-GFP. (D) FLAG-TRIM50#3 transiently transfected with HA-HDAC6 deletion mutants were treated with 25 μM of MG132 for 6 h, immunoprecipitated
with anti-HA and immunoblottedwith anti-FLAG. (E) FLAG-TRIM50#3 and FLAG-#4 empty vector, were immunoprecipitatedwith anti-FLAGantibody and immunoblottedwith anti-Ack.
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proteins, suggesting that acetylation and ubiquitination compete for the
same lysine residue (Fig. 2D). Corroborating these data, we also observed
that after microtubule depolymerization, which causes an increase of
TRIM50 acetylation level, the ubiquitination of TRIM50 protein decreased
(Fig. 3A).
3.5. The RFP domain is involved in TRIM50 cytoplasmic localization
Since we have previously shown that the ablation of C-terminal end
of TRIM50 determines a quite complete nuclear localization of TRIM50
[3,4], we speculate that the RING and Bb-Cc domains may contain
speciﬁc Nuclear Localization Sequence(s) (NLS) that can mediate
TRIM50 nuclear localization or that Nuclear Export Sequence(s) (NES)
are located close to or within the RFP domain of TRIM50. Therefore, by
bioinformatic tools we searched for NLS and NES (http://nls-mapper.
iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi; http://www.cbs.dtu.dk/services/NetNES/; http://www.sbc.su.se/~maccallr/nucpred/) in TRIM50
aminoacidic sequence, identifying three putative NES located in B-box
(from amino acid 71 to 80), Coiled-coil (203–212) and just upstream
to the RFP-like (277–289) domains, respectively. Using indirect immuno-
ﬂuorescence microscopy we measured the nucleus and cytoplasm local-
ization of three TRIM50 mutant proteins carrying a deletion of each NES
respectively (Fig. 2A).We found that only EGFP-TRIM50ΔNES3 construct
showed a predominant nuclear localization (Fig. 3B) suggesting that this
NES is the only functionally active. However, since an amount of EGFP-
TRIM50ΔNES3 retains a cytoplasmic localization, we hypothesized that
the C-terminal region and particularly the RFP domain contains some
sequences that may cooperate with NES3 in determining TRIM50 cyto-
plasmic localization. To assess that, we generated a number of constructs
carrying different deletions of the C-terminal end of TRIM50 and we
measured the amount of nuclear and cytoplasmic localization of each
construct (schematized in Fig. 2A). As reported in Fig. 3C, besides
the TRIM50-ΔRFP mutant, the TRIM50_Dom1 construct retained only a
Fig. 2. HDAC6, PCAF and p300 regulate the acetylation and/or deacetylation of TRIM50. (A) Schematic representation of TRIM50 deletion mutants. (B) HEK293 transiently transfected
with EGFP-TRIM50, EGFP-TRIM50_Dom1 andEGFP-empty vectorswere immunoprecipitatedwith anti-EGFP and anti-Ack and immunoblottedwith Ack and EGFP antibodies respectively.
(C) PAIL bioinformatic analysis of TRIM50 sequence. (D) HEK293 transiently transfected with EGFP-TRIM50, EGFP-TRIM50 K372R and EGFP-TRIM50 Del372-374 vectors, were
immunoprecipitated with anti-EGFP and immunoblotted with anti-Ack and anti-Ub antibodies. (E) HEK293 transiently transfected with EGFP-TRIM50 was treated with TSA 5 μM for
1 h and/or cotransfected with FLAG-PCAF or HA-p300, immunoprecipitated with anti-Ack and immunoblotted with anti-Ack and anti-EGFP antibodies. (F) FLAG-TRIM50#3 was
transfected with HA-HDAC6, immunoprecipitated with anti-Ack antibody and immunoblotted with FLAG and anti-Ack antibodies. (G) HDAC6+/+ and HDAC6 −/Y MEFs were transfected
with EGFP-TRIM50, immunoprecipatated with anti-EGFP and immunoblotted with Ack and EGFP antibodies, respectively. (H) HEK293 transiently transfected with EGFP-TRIM50 was
treated with 5 μM of TSA for 1 h, immunoprecipitated with anti-EGFP antibody and immunoblotted with anti-Ack.
366 C. Fusco et al. / Cellular Signalling 26 (2014) 363–369
Fig. 3. TRIM50 acetylation reduces its ubiquitination in amicrotubule-dependentmanner. (A) FLAG-TRIM50#3 treated or not 1 h in ice, stainingwithαTubulin, was immunoprecipitated
and immunoblotted with anti-Ack, FLAG, HA and Ub antibodies. Nuclear export of TRIM50 protein. (B) HeLa cells transfected with EGFP-TRIM50 mutants were analysed at confocal
microscopy. (C) The diagram shows the percentage of localization of each mutant relative of three independent experiments.
367C. Fusco et al. / Cellular Signalling 26 (2014) 363–369marginal localization of TRIM50 into the nucleus (Fig. 3C) compared
to the other domains that preserved a quite complete cytoplasmic local-
ization of TRIM50.
In addition, ectopic expression of TRIM50_Dom1ΔNES3, a construct
lacking the NES3, re-localized the protein exclusively in the nucleus
(Fig. 3B). Overall, these results suggest that the region of TRIM50,
which comprises a part of RFP domain and goes from residue 319 to
484, cooperates with NES3 to the TRIM50 cytoplasmic localization.
3.6. The RFP domain and acetylation are necessary for aggresome localiza-
tion of TRIM50
Since TRIM50 re-localizes into aggresome upon proteasome
inhibition [4], we determined the contribution of TRIM50 domains toaggresome localization. As elsewhere described TRIM50 aggresome-
localization does not depend on the E3 Ubiquitin ligase activity, as a
mutant lacking the RING domain retains the ability to localize to
aggresome [4]. Likewise, MG132 treatment was able of inducing a main
aggresome localization of TRIM50 in constructs carrying the B-box
or the C-terminal domains (Fig. 4). Conversely, deletion of RFP domain
induced a signiﬁcant localization of TRIM50 protein outside the
aggresome, in MG132 treated cells. Overall, these results substantiate
the importance of RFP domain for TRIM50 aggresome localization. Next
we asked whether the K372 residue has a role in TRIM50 aggresome
localization. In untreated cells, ectopic K372R-TRIM50 construct localized
in cytoplasmic structures as thewild-type protein; after proteasome inhi-
bition, approximately 40% of K372R-TRIM50 resulted in a complete
aggresome localization, while around 50% of the protein localizes just
Fig. 4. Aggresome localization of TRIM50 domains. (A) HeLa cells transfected with the reported TRIM50 deletion mutants were stained using HDAC6 antibody and analysed at confocal
microscopy. Where indicated the cells were treated with 25 μMMG132 for 6 h. (B) Schematic representation of TRIM50 deletion mutants used in immunoﬂuorescence assays. (C) The
diagram shows the percentage of TRIM50 localization of each mutant. The data comes from three independent experiments.
368 C. Fusco et al. / Cellular Signalling 26 (2014) 363–369partially in the aggresomewith the remaining fraction retaining a diffuse
localization. Since elimination of K372 residue, involved in both
ubiquitination and acetylation signiﬁcantly affects the localization of
TRIM50, we intimate that K372 although is neither sufﬁcient nor neces-
sary, contributes to drive TRIM50 aggresome localization.4. Discussion
Lysine acetylation is best known for its key role in the histone code,
wherein it dictates the dynamic output of gene transcription. Further
studies have indicated that acetylation occurs not only on transcription
369C. Fusco et al. / Cellular Signalling 26 (2014) 363–369but also on a variety of other cellular processes such as ubiquitination,
that do not directly involve histones [10]. In this report, we showed
that the E3 Ubiquitin ligase TRIM50 is deacetylated by HDAC6
and that intact microtubules are necessary for TRIM50 deacetylation.
Moreover this study also revealed that CBP/p300 and PCAF drive
TRIM50 acetylation at Lysine 372, a residue also involved in TRIM50
auto-ubiquitination. Our results suggest that acetylation, by competing
with the same lysine aminoacid residue, interferes with TRIM50
ubiquitination probably enhancing its own stability. Such acetylation
and ubiquitination competition has been reported for other proteins. For
instance investigations conﬁrmed the role of lysine acetylation in the con-
trol of SMAD7 stability and showed that HDAC1 or SIRT1-dependent
deacetylation, promotes SMAD7 ubiquitination and degradation [11].
Furthermore, MAML1-dependent acetylation of Notch1 ICD by p300
decreases the ubiquitination and proteosomal degradation of Notch1
ICD [12]; ﬁnally p14ARF, increases the level of p53 acetylated at lysine
382 in a nuclear chromatin-rich fraction increasing its stability and its
transcription factor activity and inhibiting its degradation [13]. HDAC6
is a TRIM50-interactor that regulates the shuttle of TRIM50 to the
aggresome when proteasome is inhibited. Findings suggest that HDAC6
is involved in the control of protein ubiquitination bydeacetylating critical
lysines [14]. Therefore, our hypothesis is that HDAC6 deacetylates
TRIM50 at K372 favouring its ubiquitination and it is subsequently
transported into aggresome associated to polyubiquitinated proteins.
TRIM proteins cluster into a constant and orderedN-Terminal region
and a ﬂexible C-Terminal tail that contain different types of functional
domains. The TRIM50 C-terminal region, including the RFP domain, is
essential for both TRIM50 cytoplasmic and aggresome localization. A
combination of bioinformatics and ﬂuorescence microscopy assays
allowed to map a functional NES in the proximity of RFP domain
which resulted necessary but not sufﬁcient for cytoplasmic localization.
Thus, we generated a number of constructs carrying deletions of
TRIM50 within its C-terminal region and we deﬁned the subcellular
localization of such constructs. Immunoﬂuorescence assays indicated
that the amino acid stretch starting from residues 319 to the end of
the protein contains additional sequences that might be involved in
the cytoplasmic retention of the protein.
Therefore, we cannot exclude a functional interface between the
C-Terminal TRIM50 region and NES3 sequence that work together for
TRIM50 cytoplasmic localization. Alternatively TRIM50 can bind to an
NES-containing protein, not yet identiﬁed.
Interestingly we demonstrated that TRIM50 interacts with p62 [4],
a nucleus-cytoplasm shuttling protein that contains two NLSs and
one NES. Nuclear p62 colocalizes with TRIM19/PML, by recruiting
polyubiquitinated proteins to PML bodies and driving their proteasomal
nuclear degradation [15]. Similarly, ectopically expressed TRIM50 and
p62 show a nuclear colocalization in presence of Leptomycin B, an anti-
biotic that inhibits nuclear export of NES containing proteins (Fusco,
unpublished data). Although in need of conﬁrmation, we can speculatethat TRIM50 by p62-mediated interaction may drive nucleus-cytosol
shuttle and regulate the protein quality control degradation system.
5. Conclusions
By bioinformatic tools, biochemical and cellular assays we showed
that the evolutionary conserved TRIM50 K372 residue competes
for post-translational protein modiﬁcations such as acetylation and
ubiquitination. TRIM50 is acetylated by PCAF and p300 and deacetylated
by HDAC6 in a microtubule-dependent manner. Overall, the data
presented here point to the existence of a potential crosstalk between
acetylation and ubiquitination in the regulation of TRIM50. This study
provides the basis for further elucidating the function of TRIM50 protein
and highlights how TRIM50 acetylation is a fundamental posttransla-
tional modiﬁcation of this E3 Ubiquitin ligase protein.
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